UCB Sa operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Stada Arzneimittel AG
sales of 2.14 billion Euro [US$2.40 billion]
of which 60%
Lonza Group AG
(4.13 billion Swiss Francs [US$4.25 billion]
of which 54%
was Specialty Ingredients), and
based in Russia
(241.48 billion Russian Rubles [US$4.28 billion]
of which 81%
UCB Sa reported sales of 4.18 billion Euro (US$4.69 billion)
December of 2016.
increase of 7.8%
versus 2015, when the company's sales were 3.88 billion Euro.